TNFRSF4 and neoplasm: Approaches to upregulate OX40 expression in the tumor microenvironment may enhance treatment effects and demonstrate greater benefit with OX40 agonists32; a study of INCAGN01949 in combination with CMP-001 (toll-like receptor nine agonist; NCT04387071) is planned to investigate such an approach.